Chugai Pharmaceutical Co., Ltd. (CHGCF)

32,43 0,00 (0,00%) Al cierre: 03:40PM EDT

Chugai Pharmaceutical Co., Ltd.

2-1-1 Nihonbashi-Muromachi
Chuo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp

Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 7604

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Osamu Okuda	President, CEO & Representative Director	1,42M	N/A	1963
Mr. Iwaaki Taniguchi	Executive VP, Head of Finance Supervisory Div., CFO & Director	N/A	N/A	1967
Toshiya Sasai	Executive of Investor Relations Group & Corporate Communications Department	N/A	N/A	N/A
Mr. Masayoshi Higuchi	VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept.	N/A	N/A	N/A
Mr. Shinji Hidaka	Executive Vice President	N/A	N/A	N/A
Mr. Junichi Ebihara	Executive Vice President	N/A	N/A	N/A
Dr. Yoshiaki Ohashi	SVP & Full-time Audit Supervisory Board Member	N/A	N/A	1960
Mr. Tetsuya Yamaguchi	Executive VP & Head of PHC Solution Unit	N/A	N/A	N/A
Mr. Yoshiyuki Yano	Executive Vice President	N/A	N/A	N/A
Dr. Shigehiro Yamada Ph.D.	Head of Sustainability Department and Full-Time Audit & Supervisory Board Member	N/A	N/A	1964

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Gobierno corporativo

El ISS Governance QualityScore de Chugai Pharmaceutical Co., Ltd., a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 1; Tablero: 7; Derechos de los accionistas: 2; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.